BIONET Corp (1784) Fair Value & Analysis
Healthcare · TW · Market cap 3.5B TWD
Fair value as of: Jun 24, 2026
Analysis
BIONET Corp (1784) currently trades at 66.80 TWD, while our model-based Fair Value estimate is 17.09 TWD — implying the stock looks roughly 74.4% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BIONET Corp (1784) undervalued?
What is the fair value of 1784?
What is the quality score of 1784?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.